NeueHealth マネジメント

マネジメント基準チェック /34

NeueHealthの CEO はMike Mikanで、 Jan2019年に任命され、の在任期間は 5.83年です。の年間総報酬は$ 9.90Mで、 13.1%給与と86.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.79%を直接所有しており、その価値は$ 320.92K 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と5.3年です。

主要情報

Mike Mikan

最高経営責任者

US$9.9m

報酬総額

CEO給与比率	13.1%
CEO在任期間	5.8yrs
CEOの所有権	0.8%
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Oct 11

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Aug 13

Bright Health Group Takes Cost Actions To Effect Turnaround

Jul 21

Bright Health Group: Examining A Dumpster Fire

Jan 04

CEO報酬分析

NeueHealth の収益と比較して、Mike Mikan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$28m
Jun 30 2024	n/a	n/a	-US$495m
Mar 31 2024	n/a	n/a	-US$510m
Dec 31 2023	US$10m	US$1m	-US$563m
Sep 30 2023	n/a	n/a	-US$825m
Jun 30 2023	n/a	n/a	-US$407m
Mar 31 2023	n/a	n/a	-US$447m
Dec 31 2022	US$10m	US$1m	-US$521m
Sep 30 2022	n/a	n/a	-US$373m
Jun 30 2022	n/a	n/a	-US$513m
Mar 31 2022	n/a	n/a	-US$450m
Dec 31 2021	US$181m	US$1m	-US$330m
Sep 30 2021	n/a	n/a	-US$534m
Jun 30 2021	n/a	n/a	-US$293m
Mar 31 2021	n/a	n/a	-US$266m
Dec 31 2020	US$5m	US$600k	-US$161m

報酬と市場: Mikeの総報酬 ($USD 9.90M ) は、 US市場 ($USD 652.28K ) の同規模の企業の平均を上回っています。

報酬と収益: Mikeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Mike Mikan (52 yo)

5.8yrs

在職期間

US$9,898,059

報酬

Mr. George Lawrence Mikan, III, also known as Mike, is Chief Executive Officer at NeueHealth, Inc. (formerly known as Bright Health Group, Inc.) (formerly Bright Health, Inc) since April 2020 and its Presi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Sheehy	Co-Founder & Chairman	9.8yrs	データなし	3.1% $ 1.3m
George Mikan	Vice Chairman	5.8yrs	US$9.90m	0.79% $ 320.9k
Jay Matushak	Chief Financial Officer	1.5yrs	US$1.77m	0.11% $ 46.9k
Tomas Orozco	Executive Vice President of Consumer Care	less than a year	US$1.59m	0.062% $ 25.2k
Jeffrey Scherman	Chief Accounting Officer	no data	データなし	0.044% $ 18.2k
Jeff Craig	General Counsel & Corporate Secretary	2.7yrs	US$832.55k	0.042% $ 17.0k
Stacy Conti	Chief People Officer	no data	データなし	データなし
Joaquin Baralt	President of Value-Based Care	no data	データなし	データなし

2.1yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: NEUEの経営陣は経験豊富であると考えられます ( 2.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Sheehy	Co-Founder & Chairman	9.8yrs	データなし	3.1% $ 1.3m
George Mikan	Vice Chairman	5.8yrs	US$9.90m	0.79% $ 320.9k
Andrew Slavitt	Independent Director	3.3yrs	US$153.68k	0.17% $ 67.6k
Jeffrey Immelt	Independent Director	4.6yrs	US$173.68k	0.16% $ 66.4k
Mohamad Makhzoumi	Independent Director	8.7yrs	US$163.68k	0.072% $ 29.4k
Linda Gooden	Independent Director	5.8yrs	US$163.68k	1.21% $ 494.3k
Manuel Kadre	Independent Lead Director	4yrs	US$188.68k	0.28% $ 113.9k
Stephen H. Kraus	Independent Director	8.7yrs	US$163.68k	0.072% $ 29.4k
Matthew Manders	Independent Director	2.7yrs	US$153.68k	0.076% $ 30.9k
Kedrick Adkins	Independent Director	4.8yrs	US$178.68k	1.21% $ 494.3k

5.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: NEUEの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

NeueHealth マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Recent updates

Third quarter 2024 earnings released: US$6.78 loss per share (vs US$72.52 loss in 3Q 2023)

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Insufficient new directors

Second quarter 2024 earnings released: US$6.42 loss per share (vs US$8.55 loss in 2Q 2023)

NeueHealth, Inc. Updates Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Financial position

NeueHealth, Inc. announced that it has received $150 million in funding

New minor risk - Shareholder dilution

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$2.31 loss per share (vs US$9.04 loss in 1Q 2023)

NeueHealth, Inc. to Report Q1, 2024 Results on May 08, 2024

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$70.72 loss per share (vs US$98.28 loss in FY 2022)

NeueHealth, Inc. Provides Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Third quarter 2023 earnings released: US$72.52 loss per share (vs US$40.11 loss in 3Q 2022)

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Revenue and earnings growth

Bright Health Group, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Consensus EPS estimates upgraded to US$51.32 loss

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Revises Its Financial Outlook for 2023

Bright Health Group, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 47% to US$200

Florence Labs, Inc. acquired Zipnosis, Inc. from Bright Health Group, Inc. (NYSE:BHG).

Price target decreased by 14% to US$1.70

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Price target decreased by 24% to US$1.50

Consensus EPS estimates fall by 14%

Full year 2022 earnings released: US$1.23 loss per share (vs US$3.02 loss in FY 2021)

Bright Health Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Bright Health Group: Stock Price Has Been Too Heavily Beaten Down

Bright Health Group expects FY23 revenue to be below consensus

Independent Director recently bought US$248k worth of stock

Bright Health Group Receives Continued Listing Standard Notice from NYSE

Bright Health receives non-compliance notice from NYSE

Independent Lead Director recently bought US$294k worth of stock

Price target decreased to US$2.07

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2022

Bright Health Group reports Q3 mixed earnings; revises Fy22 guidance

Bright Health Group, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Bright Health Group, Inc. announced that it has received $175 million in funding from a group of investors

Bright Health Group, Inc. Provides Revenue Guidance for the Year 2023

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Provides Revenue Guidance for the Full Year 2022

Bright Health Group, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Bright Health Group Takes Cost Actions To Effect Turnaround

Price target decreased to US$2.76

Bright Health Group, Inc.(NYSE:BHG) dropped from Russell 2000 Growth Index

Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Bright Health Group, Inc. to Report Q1, 2022 Results on May 04, 2022

Bright Health Group, Inc., Annual General Meeting, May 13, 2022

Consensus forecasts updated

マネジメント基準チェック /34